Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus infection in chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2018 clinical practice guideline

Craig E. Gordon, Marina C. Berenguer, Wahid Doss, Fabrizio Fabrizi, Jacques Izopet, Vivekanand Jha, Nassim Kamar, Bertram L. Kasiske, Ching Lung Lai, Jose M. Morales, Priti R. Patel, Stanislas Pol, Marcelo O. Silva, Ethan M. Balk, Amy Earley, Mengyang Di, Michael Cheung, Michel Jadoul, Paul Martin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is an extensive update of KDIGO's 2008 guideline on HCV infection in CKD. This update reflects the major advances since the introduction of directacting antivirals (DAAs) in the management of HCV infection in the CKD population. Methods: The KDIGO work group tasked with developing the HCV and CKD guideline defined the scope of the guideline, gathered evidence, determined topics for systematic review, and graded the quality of evidence previously summarized by the evidence review team. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach was used to appraise the quality of evidence and rate the strength of the recommendations. Searches of the Englishlanguage literature were conducted through May 2017 and were supplemented with targeted searches for studies of DAA treatment and with abstracts from nephrology, hepatology, and transplantation conferences. A review process involving many stakeholders, subject matter experts, and industry and national organizations informed the guideline's final modification. Recommendation: The updated guideline comprises 66 recommendations. This synopsis focuses on 32 key recommendations pertinent to the prevention, diagnosis, treatment, and management of HCV infection in adult CKD populations.

Original languageEnglish (US)
Pages (from-to)496-504
Number of pages9
JournalAnnals of internal medicine
Volume171
Issue number7
DOIs
StatePublished - Oct 1 2019

Fingerprint

Kidney Diseases
Virus Diseases
Chronic Renal Insufficiency
Practice Guidelines
Hepacivirus
Guidelines
Antiviral Agents
Nephrology
Gastroenterology
Population
Industry
Transplantation
Organizations

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus infection in chronic kidney disease : Synopsis of the kidney disease: Improving global outcomes 2018 clinical practice guideline. / Gordon, Craig E.; Berenguer, Marina C.; Doss, Wahid; Fabrizi, Fabrizio; Izopet, Jacques; Jha, Vivekanand; Kamar, Nassim; Kasiske, Bertram L.; Lai, Ching Lung; Morales, Jose M.; Patel, Priti R.; Pol, Stanislas; Silva, Marcelo O.; Balk, Ethan M.; Earley, Amy; Di, Mengyang; Cheung, Michael; Jadoul, Michel; Martin, Paul.

In: Annals of internal medicine, Vol. 171, No. 7, 01.10.2019, p. 496-504.

Research output: Contribution to journalArticle

Gordon, CE, Berenguer, MC, Doss, W, Fabrizi, F, Izopet, J, Jha, V, Kamar, N, Kasiske, BL, Lai, CL, Morales, JM, Patel, PR, Pol, S, Silva, MO, Balk, EM, Earley, A, Di, M, Cheung, M, Jadoul, M & Martin, P 2019, 'Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus infection in chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2018 clinical practice guideline', Annals of internal medicine, vol. 171, no. 7, pp. 496-504. https://doi.org/10.7326/M19-1539
Gordon, Craig E. ; Berenguer, Marina C. ; Doss, Wahid ; Fabrizi, Fabrizio ; Izopet, Jacques ; Jha, Vivekanand ; Kamar, Nassim ; Kasiske, Bertram L. ; Lai, Ching Lung ; Morales, Jose M. ; Patel, Priti R. ; Pol, Stanislas ; Silva, Marcelo O. ; Balk, Ethan M. ; Earley, Amy ; Di, Mengyang ; Cheung, Michael ; Jadoul, Michel ; Martin, Paul. / Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus infection in chronic kidney disease : Synopsis of the kidney disease: Improving global outcomes 2018 clinical practice guideline. In: Annals of internal medicine. 2019 ; Vol. 171, No. 7. pp. 496-504.
@article{8a99469cb5fc4ed8b5c13b861ecf38d3,
title = "Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus infection in chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2018 clinical practice guideline",
abstract = "Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is an extensive update of KDIGO's 2008 guideline on HCV infection in CKD. This update reflects the major advances since the introduction of directacting antivirals (DAAs) in the management of HCV infection in the CKD population. Methods: The KDIGO work group tasked with developing the HCV and CKD guideline defined the scope of the guideline, gathered evidence, determined topics for systematic review, and graded the quality of evidence previously summarized by the evidence review team. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach was used to appraise the quality of evidence and rate the strength of the recommendations. Searches of the Englishlanguage literature were conducted through May 2017 and were supplemented with targeted searches for studies of DAA treatment and with abstracts from nephrology, hepatology, and transplantation conferences. A review process involving many stakeholders, subject matter experts, and industry and national organizations informed the guideline's final modification. Recommendation: The updated guideline comprises 66 recommendations. This synopsis focuses on 32 key recommendations pertinent to the prevention, diagnosis, treatment, and management of HCV infection in adult CKD populations.",
author = "Gordon, {Craig E.} and Berenguer, {Marina C.} and Wahid Doss and Fabrizio Fabrizi and Jacques Izopet and Vivekanand Jha and Nassim Kamar and Kasiske, {Bertram L.} and Lai, {Ching Lung} and Morales, {Jose M.} and Patel, {Priti R.} and Stanislas Pol and Silva, {Marcelo O.} and Balk, {Ethan M.} and Amy Earley and Mengyang Di and Michael Cheung and Michel Jadoul and Paul Martin",
year = "2019",
month = "10",
day = "1",
doi = "10.7326/M19-1539",
language = "English (US)",
volume = "171",
pages = "496--504",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "7",

}

TY - JOUR

T1 - Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus infection in chronic kidney disease

T2 - Synopsis of the kidney disease: Improving global outcomes 2018 clinical practice guideline

AU - Gordon, Craig E.

AU - Berenguer, Marina C.

AU - Doss, Wahid

AU - Fabrizi, Fabrizio

AU - Izopet, Jacques

AU - Jha, Vivekanand

AU - Kamar, Nassim

AU - Kasiske, Bertram L.

AU - Lai, Ching Lung

AU - Morales, Jose M.

AU - Patel, Priti R.

AU - Pol, Stanislas

AU - Silva, Marcelo O.

AU - Balk, Ethan M.

AU - Earley, Amy

AU - Di, Mengyang

AU - Cheung, Michael

AU - Jadoul, Michel

AU - Martin, Paul

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is an extensive update of KDIGO's 2008 guideline on HCV infection in CKD. This update reflects the major advances since the introduction of directacting antivirals (DAAs) in the management of HCV infection in the CKD population. Methods: The KDIGO work group tasked with developing the HCV and CKD guideline defined the scope of the guideline, gathered evidence, determined topics for systematic review, and graded the quality of evidence previously summarized by the evidence review team. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach was used to appraise the quality of evidence and rate the strength of the recommendations. Searches of the Englishlanguage literature were conducted through May 2017 and were supplemented with targeted searches for studies of DAA treatment and with abstracts from nephrology, hepatology, and transplantation conferences. A review process involving many stakeholders, subject matter experts, and industry and national organizations informed the guideline's final modification. Recommendation: The updated guideline comprises 66 recommendations. This synopsis focuses on 32 key recommendations pertinent to the prevention, diagnosis, treatment, and management of HCV infection in adult CKD populations.

AB - Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is an extensive update of KDIGO's 2008 guideline on HCV infection in CKD. This update reflects the major advances since the introduction of directacting antivirals (DAAs) in the management of HCV infection in the CKD population. Methods: The KDIGO work group tasked with developing the HCV and CKD guideline defined the scope of the guideline, gathered evidence, determined topics for systematic review, and graded the quality of evidence previously summarized by the evidence review team. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach was used to appraise the quality of evidence and rate the strength of the recommendations. Searches of the Englishlanguage literature were conducted through May 2017 and were supplemented with targeted searches for studies of DAA treatment and with abstracts from nephrology, hepatology, and transplantation conferences. A review process involving many stakeholders, subject matter experts, and industry and national organizations informed the guideline's final modification. Recommendation: The updated guideline comprises 66 recommendations. This synopsis focuses on 32 key recommendations pertinent to the prevention, diagnosis, treatment, and management of HCV infection in adult CKD populations.

UR - http://www.scopus.com/inward/record.url?scp=85072896762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072896762&partnerID=8YFLogxK

U2 - 10.7326/M19-1539

DO - 10.7326/M19-1539

M3 - Article

C2 - 31546256

AN - SCOPUS:85072896762

VL - 171

SP - 496

EP - 504

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 7

ER -